文献速递神经免疫

儿童视神经脊髓炎谱系疾病的治疗反应

Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder.
PubMed 文献 · Neurology · 2022-12-02

这项回顾性队列研究评估了美国12家儿童多发性硬化中心随访的91例儿童视神经脊髓炎谱系疾病(NMOSD)患者,其中77例AQP4抗体阳性、14例双抗体阴性。利妥昔单抗、吗替麦考酚酯、硫唑嘌呤和静脉注射免疫球蛋白(IVIg)等初始疾病修正治疗(DMT)的年化复发率(ARR)分别为0.25、0.33、0.40和0.54,而未经治疗组为0.97;DMT尤其利妥昔单抗与AQP4阳性儿童ARR降低相关,但未发现对EDSS进展有统计学显著影响。

要点

  • 利妥昔单抗组ARR为0.25(95%CI 0.13-0.49),低于未经治疗组的0.97(95%CI 0.58-1.60)。
  • AQP4阳性亚组中利妥昔单抗ARR为0.28(95%CI 0.14-0.55),未经治疗组为0.91(95%CI 0.53-1.56)。
  • 任何初始DMT对EDSS评分增加≥1.0分的残疾进展均无统计学显著影响。

核心结论

  • 使用DMT尤其利妥昔单抗与AQP4阳性儿童NMOSD患者年化复发率降低相关。
  • 本研究提供IV级证据支持上述关联。

研究设计与样本

  • 回顾性队列研究,纳入美国12家儿童多发性硬化中心随访的91例儿童NMOSD患者(77例AQP4阳性,14例双抗体阴性)。
  • 采用负二项回归评估初始DMT对年化复发率的影响,采用Cox比例风险模型分析至残疾进展(EDSS评分增加≥1.0分)的时间。

主要发现

  • 全部血清学组中,利妥昔单抗ARR为0.25(95%CI 0.13-0.49),吗替麦考酚酯为0.33(95%CI 0.19-0.58),硫唑嘌呤为0.40(95%CI 0.13-1.24),IVIg为0.54(95%CI 0.28-1.04),未经治疗组为0.97(95%CI 0.58-1.60)。
  • AQP4阳性亚组中,利妥昔单抗ARR为0.28(95%CI 0.14-0.55),吗替麦考酚酯为0.39(95%CI 0.21-0.70),硫唑嘌呤为0.41(95%CI 0.13-1.29),IVIg为0.54(95%CI 0.23-1.26),未经治疗组为0.91(95%CI 0.53-1.56)。
  • 任何初始DMT对EDSS进展均无统计学显著影响。

临床怎么用

  • 原文未据此给出推荐,作者结论为使用DMT尤其利妥昔单抗与AQP4阳性儿童NMOSD患者年化复发率降低相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition, which can lead to significant disability, and up to 3%-5% of the cases have a pediatric onset. There are limited studies to guide physicians in disease-modifying treatment (DMT) choices for children with NMOSD. METHODS: This retrospective cohort study evaluated children with NMOSD cases followed at 12 clinics in the US Network of Pediatric MS Centers. Cases were classified as aquaporin-4 antibody positive (AQP4+) and double seronegative (DS) when negative for AQP4+ and for myelin oligodendrocyte glycoprotein (MOG) antibody. The effect of initial DMTs including rituximab, mycophenolate, azathioprine, and IV immunoglobulin (IVIg) on the annualized relapse rate (ARR) was assessed by negative binomial regression. Time to disability progression (EDSS score increase ≥1.0 point) was modeled with a Cox proportional-hazards model. RESULTS: A total of 91 children with NMOSD were identified: 77 AQP4+ and 14 DS (85.7% females; 43.2% White and 46.6% African American). Eighty-one patients were started on a DMT, and 10 were treatment naive at the time of the analysis. The ARR calculated in all serogroups was 0.25 (95% CI 0.13-0.49) for rituximab, 0.33 (95% CI 0.19-0.58) for mycophenolate, 0.40 (95% CI 0.13-1.24) for azathioprine, and 0.54 (95% CI 0.28-1.04) for IVIg. The ARR in the AQP4+ subgroup was 0.28 (95% CI 0.14-0.55) for rituximab, 0.39 (95% CI 0.21-0.70) for mycophenolate, 0.41 (95% CI 0.13-1.29) for azathioprine, and 0.54 (95% CI 0.23-1.26) for IVIg. The ARR in the treatment-naive group was 0.97 (95% CI 0.58-1.60) in all serogroups and 0.91 (95% CI 0.53-1.56) in the AQP4+ subgroup. None of the initial DMT had a statistically significant effect on EDSS progression. DISCUSSION: The use of DMTs, particularly rituximab, is associated with a lowered annualized relapse rate in children with NMOSD AQP4+. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that use of disease-modifying treatments is associated with a lowered annualized relapse rate in children with NMOSD AQP4+.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Pizzolato Umeton R, Waltz M, Aaen GS, et al. Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder. Neurology. 2022. PMID: 36460473. doi:10.1212/WNL.0000000000201625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。